TEST BANK
Goodman and Gilman's The
Pharmacological Basis of Therapeutics
14th Edition
Author(s)Laurence Brunton; Bjorn Knollmann
Print ISBN: 9781264258079
,Question 1
A researcher studying the historical origins of pharmacology explains
that several important drugs were initially identified after observations
of biological effects produced by plant preparations. Which discovery
approach best characterizes this early process?
A. Target-based drug design
B. Serendipitous observation of pharmacological effects
,C. Computer-assisted molecular docking
D. High-throughput receptor screening
Correct Answer:
B. Serendipitous observation of pharmacological effects
Rationale:
B is correct because early drug discovery frequently began with
observed biological effects of plant extracts or naturally occurring
substances without prior knowledge of a specific molecular target. A is
incorrect because target-based design requires knowledge of a
biological target. C is incorrect because molecular docking is a modern
computational technique. D is incorrect because high-throughput
screening depends on automated testing of large compound libraries
and developed much later.
Question 2
Which characteristic of natural products most directly explains why they
have remained useful starting points for drug discovery?
A. They are always orally bioavailable
B. They have limited chemical diversity
C. They can provide structurally diverse biologically active molecules
D. They rarely require chemical modification
Correct Answer:
C. They can provide structurally diverse biologically active molecules
Rationale:
C is correct because natural products can provide chemically diverse
molecules with intrinsic biological activity, making them valuable
starting points for identifying pharmacological leads. A is incorrect
, because natural products may have poor oral absorption or other
unfavorable pharmacokinetic properties. B is incorrect because
chemical diversity is a major strength rather than a limitation. D is
incorrect because natural-product leads may require substantial
modification to improve potency, selectivity, safety, or drug-like
properties.
Question 3
A newly identified molecule produces a promising biological effect
against a validated disease-related target but has suboptimal selectivity
and pharmacokinetic properties. Which term best describes the
molecule at this stage?
A. Approved therapeutic agent
B. Lead compound
C. Clinical endpoint
D. Pharmacovigilance signal
Correct Answer:
B. Lead compound
Rationale:
B is correct because a lead compound has promising biological activity
but generally requires further optimization before it can become a
development candidate. A is incorrect because approval requires
successful development and regulatory review. C is incorrect because a
clinical endpoint describes an outcome measured in a clinical study. D is
incorrect because pharmacovigilance concerns monitoring and
evaluation of drug safety, particularly after exposure in clinical use.
Question 4
Goodman and Gilman's The
Pharmacological Basis of Therapeutics
14th Edition
Author(s)Laurence Brunton; Bjorn Knollmann
Print ISBN: 9781264258079
,Question 1
A researcher studying the historical origins of pharmacology explains
that several important drugs were initially identified after observations
of biological effects produced by plant preparations. Which discovery
approach best characterizes this early process?
A. Target-based drug design
B. Serendipitous observation of pharmacological effects
,C. Computer-assisted molecular docking
D. High-throughput receptor screening
Correct Answer:
B. Serendipitous observation of pharmacological effects
Rationale:
B is correct because early drug discovery frequently began with
observed biological effects of plant extracts or naturally occurring
substances without prior knowledge of a specific molecular target. A is
incorrect because target-based design requires knowledge of a
biological target. C is incorrect because molecular docking is a modern
computational technique. D is incorrect because high-throughput
screening depends on automated testing of large compound libraries
and developed much later.
Question 2
Which characteristic of natural products most directly explains why they
have remained useful starting points for drug discovery?
A. They are always orally bioavailable
B. They have limited chemical diversity
C. They can provide structurally diverse biologically active molecules
D. They rarely require chemical modification
Correct Answer:
C. They can provide structurally diverse biologically active molecules
Rationale:
C is correct because natural products can provide chemically diverse
molecules with intrinsic biological activity, making them valuable
starting points for identifying pharmacological leads. A is incorrect
, because natural products may have poor oral absorption or other
unfavorable pharmacokinetic properties. B is incorrect because
chemical diversity is a major strength rather than a limitation. D is
incorrect because natural-product leads may require substantial
modification to improve potency, selectivity, safety, or drug-like
properties.
Question 3
A newly identified molecule produces a promising biological effect
against a validated disease-related target but has suboptimal selectivity
and pharmacokinetic properties. Which term best describes the
molecule at this stage?
A. Approved therapeutic agent
B. Lead compound
C. Clinical endpoint
D. Pharmacovigilance signal
Correct Answer:
B. Lead compound
Rationale:
B is correct because a lead compound has promising biological activity
but generally requires further optimization before it can become a
development candidate. A is incorrect because approval requires
successful development and regulatory review. C is incorrect because a
clinical endpoint describes an outcome measured in a clinical study. D is
incorrect because pharmacovigilance concerns monitoring and
evaluation of drug safety, particularly after exposure in clinical use.
Question 4
